Schwab Andrew J. sold $1.6M of CAMP (indirect holdings)

CAMP4 Therapeutics (CAMP) received UK authorization to include sites in its Phase 1/2 trial for CMP-002, a potential treatment for SYNGAP1-related disorder. The trial, set to begin in Q4 2026, follows earlier approvals in Australia and Argentina. CAMP stock is currently at $4.35, up 0.46%.

CAMP4 Therapeutics (Nasdaq: CAMP) received UK authorization to include sites in its Phase 1/2 trial for CMP-002, a potential treatment for SYNGAP1-related disorder. The company plans to start the trial in 4Q 2026, following clearances in Australia and Argentina. CMP-002 aims to restore SYNGAP protein levels, with no approved therapies currently available for this rare disorder.

CAMP4 Therapeutics (CAMP) reported Q2 2026 net loss of $33.5M, or $0.58/share, versus $12.6M, or $0.62/share, a year earlier. The wider loss was mainly due to a $20.9M non-cash derivative fair value change. R&D rose to $10.8M. CAMP4 received Australia and Argentina clearance for a Phase 1/2 CMP-002 trial, expected to start in Q4 2026, and raised $50.1M, extending runway to end-2028.

Camp4 Therapeutics Corp (CAMP) filed an SEC Form 8-K — Results of Operations and Financial Condition. CAMP4 Reports Second Quarter 2026 Financial Results and Corporate Highlights Secured regulatory clearance in two jurisdictions to initiate first-in-human Phase 1/2 clinical trial of CMP-002 in patients with SYNGAP-1 related disorder; trial initiation anticipated in the fourth qua

SGF FANG Holdings, LP sold 9,079,675 shares of Diamondback Energy, Inc. (FANG) at $205.26 ($1.86B total) on 2026-09-16. Filed jointly with Greth Lyndal (10% owner).

Campos Luis purchased 80,000 indirectly-held shares of BETTERWARE DE MEXICO, S.A.P.I. DE C.V (BWMX) at an average of $16.34 ($16.26–$16.44, $1.31M total) across 2 trades over 2026-09-15 to 2026-09-16.